66 -12 (50) 2022 — Rizaeva M.J. — THE CHOICE OF RELIEF OF THE PERSISTENT FORM OF ATRIAL FIBRILLATION UNDER INTENSIVE CARE

THE CHOICE OF RELIEF OF THE PERSISTENT FORM OF ATRIAL FIBRILLATION UNDER INTENSIVE CARE

Rizaeva M.J. Bukhara State Medical Institute, Bukhara branch of RCEMC. Bukhara, Uzbekistan

Resume

Atrial fibrillation (AF) is considered as a variation of supraventricular tachyarrhythmia with chaotic atrial electrical activity with a pulse rate of 350 or more per minute, which excludes the possibility of their coordinated contraction [1]. AF continues to be one of the most urgent problems of modern cardiology. It is the most common cardiac arrhythmia, with an incidence of 1–2% in the general population [2]. The analysis is based on the conclusions about the preference of the heart rate control strategy in patients with AF and about the safety and effectiveness of electrical cardioversion. The most significant threat to AF is thromboembolic complications, for example, the risk of stroke increases by 5 times [3]. These complications, occurring against the background of AF, tend to recur, more often lead to disability and even death [8,9].

Key words: electrical cardioversion, atrial fibrillation, persistent form, heart rate.

First page

382

Last page

385

For citation: Rizaeva M.J. – THE CHOICE OF RELIEF OF THE PERSISTENT FORM OF ATRIAL FIBRILLATION UNDER INTENSIVE CARE //New Day in Medicine 12(50)2022 382-385 https://clck.ru/33Berd

LIST OF REFERENCES:

1. Струтынский А.В. Электрокардиограмма. Анализ и интерпретация. — /М: МЕДпресс-информ, 2009. — С. 120—123. — 224 с. — 
2. Кенжаев М.Л., Ризаева М.Ж. Выявление предикторов фибрилляции предсердий у больных ишемической болезнью сердца. //Новый день в медицине, 2020. (2), 403-406.
3. Кенжаев М.Л., Ризаева М.Ж. Клиническое течение фибрилляции предсердий у больных ишемической болезнью сердца. //Наука и инновации-современные концепции 2020. (pp. 103-109).
4. Турдиев У.М., Болтаев Э.Б., Кодиров М.Д. Показатели цитокинов у больных с острым коронарным синдромом в зависимомти от вида антитромботическиой терапии. //Высшая школа: научные исследования 2020. (pp. 93-97).
5. RSC, RSSA, RACVS guidelines for the electrophysiological studies, catheter ablation and implantable use of antiarrhythmic devices. Available at: http://www.vnoa.ru/literature/Recomend2013.pdf. Accessed by 1 5/08/2014. Russian (Клинические рекомендации РКО, ВНОА И АССХ по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Доступно на: http://www.vnoa.ru/literature/Recomend2013.pdf. Проверено 1 5.08.201 4).
6. Hylek E.M., Go A.S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. //N Engl J Med 2003; 349: 1 019-26.
7. Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrillation: a systematic review. //Am J Med 2006; 1 19: 448 e1-e19.
8. Roy D., Talajic M., Nattel S. et al. Rhythm control versus rate control for atrial fibrillation and heart failure //N. Engl. J. Med.- 2008. – Vol. 358. – P. 2667-2677.
9. Hsu L.F., Jais P., Sanders P. et al. Catheter ablation for atrial fibrillation in congestive heart failure //N. Engl. J. Med. – 2004. – Vol. 351. – P. 2373-2383.
10. Khan M.N., Jais P., Cummings J. et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure //N. Engl. J. Med. – 2008. – Vol. 359. – P. 1778-1785.
11. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. //Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803-17.
12. Ezekowitz M.D., Cappato R. Klein A.L., Camm A.J. et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in patients with nonvalvular atrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion //Am. Heart J. – 2014. – Vol. 167(5). – P. 646-652.
13. Rizaeva M.Z. The clinical course of atrial fibrillation in patients with coronary heart disease. //European journal of molecular medicine, 2022. 2(1).
14. Koyirov A.K., Shirinov D.K., Rakhimov M.M., Boltayev E.B., Galilov A.A. Non-invasive lung ventilation in acute respiratory failure caused by new coronavirus infection COVID-19. //Новый день в медицине, 2021. (1)107-114.
15. Qoyirov A.Q., Kenjaev S.R., Xaitov S.SH. Egamova N.T., Boltaev E.B., The role of delirium in patients with myocardial infarction of complicated acute heart failure //New Day in Medicine 3(31)2020 68-71
16. Rizayeva Malika Jamolovna. (2020). Improvement of methods of treatment of persistent atrial fibrillation in patients with ischemic heart disease. //International Engineering Journal For Research Development, 5(SPECIAL ISSUE), 7. https://doi.org/10.17605/OSF.IO/ZFJW9
17. Boltayev E. Choice of respiratory therapy in severe patients with new coronavirus infection COVID-19. Достижения науки и образования Учредители: Олимп, 2020(8), 70-74.
18. Пўлатова Ш.Х. Особенности ТЛТ у больных острым инфарктом миокарда  //Шошилинч тиббиёт ахборотномаси. Тошкент 2019. (6) С.89-92 (14.00.00; № 11)
19. Pulatova Sh.H. Method of improving vasopressor therapy for acute myocardial infarction complied with cardiogenetic shock //American Journal Of Medicine And Medical Sciences. 2020.10(11).Р. 911-913
20. Pulatova Sh.H. Improvement of treatment of patients with acute heart failure, a comparative evaluation of the effectiveness of dobutamine and levosimendan //World Journal Of Pharmaceutical Research. 2020. 9(6) 2283-2288.